Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

NCT00528983 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes (MDS)
Chronic Myelomonocytic Leukemia (CMML)
Acute Myelogenous Leukemia (AML)

Interventions

DRUG: Subcutaneous (SC) Azacitidine
DRUG: Oral Azacitidine
DRUG: Oral Azacitidine

Sponsor

Celgene